What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on Thoratec with 10 of 17 analysts rating it hold. Analysts don't like Thoratec as much as competitor Heartware, International overall. Six out of 11 analysts rate Heartware, International a buy compared to seven of 17 for Thoratec.
- Revenue Forecasts: On average, analysts predict $107.4 million in revenue this quarter. That would represent a rise of 10.1% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of 30 per share. Estimates range from $0.27 to $0.33.
What our community says:
CAPS All-Stars are enthusiastically backing the stock, with 86.7% giving it an "outperform" rating. Most of the community concurs with the All-Stars, with 87.3% granting it a rating of "outperform." Fools are gung-ho about Thoratec, though the message boards have been quiet lately with only 92 posts in the past 30 days. Despite the majority sentiment in favor of Thoratec, the stock has a middling CAPS rating of three out of five stars.
Thoratec's profit has risen year-over-year by an average of 26.7% over the past five quarters. The company's revenue has now risen for two straight quarters.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Thoratec now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.